Skip to main content

Advertisement

SpringerLink
Log in

Low Dose Prophylaxis in Hemophilia Care

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Hemophilia is an inherited bleeding disorder which causes impaired blood clotting. The severity of disease depends on the type of Hemophilia, level of clotting factor concentrate (CFC), phenotypic heterogeneity and the development of inhibitors. The currently accepted standard of care of this disease is prophylaxis therapy (PT) with CFC. Prophylaxis therapy for Hemophilia is given in developed countries for the last few decades. On the contrary, episodic therapy (ET) is still the mode of treatment in middle and low income countries. ET is documented to have several potential risks such as increased bleeding rate, disability due to haemarthrosis, poor quality of life and increased chances of mortality. Several studies conducted in developed countries have confirmed the clinical efficacy of PT in Hemophilia treatment. Currently, there exist several challenges for implementation of this effective treatment in resource poor nations. Low dose prophylaxis (LDP) has been developed as a solution to minimize these challenges and to provide better care for subjects with Hemophilia from low resource countries. The impact of LDP was evaluated by several recent studies and the reported clinical outcomes seem to suggest an optimistic future for this line of therapy. Several themes related to Hemophilia care like inhibitor development, tolerance, pharmacokinetics of CFCs and cost–benefit analysis of different prophylaxis regimens are currently understood poorly. These distinct elements are highly relevant to assess the actual benefits of LDP regimen in a global scale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaadan AN, Angrini M (2010) Who discovered hemophilia? Available via DIALOG. https://www.ishim.net/Articles/WhoDiscoveredHemophilia.pdf. Accessed 16 Jan 2019

  2. Berntorp E (2013) History of prophylaxis. Haemophilia 19:163–165

    CAS  PubMed  Google Scholar 

  3. WFH: guidelines for the management of hemophilia 2nd edn. Available via DIALOG. https://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed 21 Jun 2018

  4. Coppola A et al (2010) Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 1:183–195

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Azza A, Tantawy G (2010) Molecular genetics of hemophilia A: clinical perspectives. Egypt J Med Hum Genet 11:105–114

    Google Scholar 

  6. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M (2010) A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16(1):20–32

    CAS  PubMed  Google Scholar 

  7. WFH Report (2016) Annual report of the National Haemophilia Foundation. Available via DIALOG. https://www1.wfh.org/publications/files/pdf-1690.pdf. Accessed 13 Aug 2018

  8. Makris M (2012) Prophylaxis in haemophilia should be life-long. Blood Transfus 10(2):165–168

    PubMed  PubMed Central  Google Scholar 

  9. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S (2006) Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 12:241–247

    CAS  PubMed  Google Scholar 

  10. Mannucci PM (2008) Back to the future: a recent history of haemophilia treatment. Haemophilia 14(3):10–18

    PubMed  Google Scholar 

  11. Franchini M, Mannuccio P (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7:24

    PubMed  PubMed Central  Google Scholar 

  12. Mannucci PM (2002) Hemophilia and related bleeding disorders: a story of dismay and success. Hematol Am Soc Hematol Educ Program 2002:1–9

    Google Scholar 

  13. White GC, McMillan CW, Kingdon HS, Shoemaker CB (1989) Use of recombinant hemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 320(3):166–170

    PubMed  Google Scholar 

  14. Carr ME, Tortella BJ (2015) Emerging and future therapies for hemophilia. J Blood Med 6:245–255

    PubMed  PubMed Central  Google Scholar 

  15. Hemophilia federation of America document. Available via DIALOG. www.hemophiliafed.org/bleeding-disorders/hemophilia/treatment. Accessed 22 July 2018

  16. Srivastava A (2004) Dose and response in hemophilia: optimization of factor replacement therapy. Br J Hematol 127(1):12–25

    Google Scholar 

  17. O’Mahony B, Black C (2005) Expanding hemophilia care in developing countries. Semin Thromb Hemost 31(5):561–568

    PubMed  Google Scholar 

  18. Tezanos Pinto M, Ortiz Z (2004) Haemophilia in the developing world: successes, frustrations and opportunities. Haemophilia Suppl 4:14–19

    Google Scholar 

  19. Simpson ML, Valentino LA (2012) Management of joint bleeding in hemophilia. Expert Rev Hematol 5(4):459–468

    CAS  PubMed  Google Scholar 

  20. Carlsson M, Berntorp E, Björkman S, Lindvall K (1993) Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 51(4):247–252

    CAS  PubMed  Google Scholar 

  21. Aledort LM, Hashmeyer RH, Pettersson H (1994) A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Int Med 236(4):391–399

    CAS  Google Scholar 

  22. Ljung RCR, Aronis-Vournas S, Kurnik-Auberger K et al (2000) Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 6:619–624

    CAS  PubMed  Google Scholar 

  23. Ripa T, Scaraggi FA, Ciavarella N (1978) Early treatment of hemophilia with minimal doses of factor VIII or factor IX. Blood 51:763

    CAS  PubMed  Google Scholar 

  24. Allain JP (1979) Dose requirement for replacement therapy in hemophilia A. J Thromb Haemost 42(3):825–831

    CAS  Google Scholar 

  25. Rossbach H-C (2010) Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. Vasc Health Risk Manag 6:59–68

    CAS  PubMed  PubMed Central  Google Scholar 

  26. van den Berg HM, Fischer K, van der Bom JG (2003) Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 9(Suppl. 1):27–31

    PubMed  Google Scholar 

  27. The European Paediatric Network for Haemophilia Management (PedNet Registry) (PedNet) (2016). Available via DIALOG. https://clinicaltrials.gov/ct2/show/NCT02979119. Accessed 16 Jan 2018

  28. Manco-Johnson MJ, Abshire TC, Shapiro AD et al (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. Joint Outcome Study. N Engl J Med 357(6):535–544

    CAS  PubMed  Google Scholar 

  29. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, The ESPRIT Study Group (2011) A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 9:700–710

    CAS  PubMed  Google Scholar 

  30. Manco-Johnson MJ et al (2013) Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 11(6):1119–1127

    CAS  PubMed  Google Scholar 

  31. Tagliaferri A et al (2015) Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. J Thromb Haemost 114(1):35–45

    Google Scholar 

  32. Fischer K et al (2013) Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 122(7):1129–1136

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Petrini P (2001) What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 7(1):99–102

    CAS  PubMed  Google Scholar 

  34. Feldman BN, Pai M, Rivard GE et al (2006) Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 4(6):1228–1236

    CAS  PubMed  Google Scholar 

  35. Steen Carlsson K et al (2003) On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 9:555–566

    CAS  PubMed  Google Scholar 

  36. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E (1999) Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 105(4):1109–1113

    CAS  PubMed  Google Scholar 

  37. Fischer K et al (2002) The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 99(7):2337–2341

    CAS  PubMed  Google Scholar 

  38. van den Berg HM et al (2001) Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 112(3):561–565

    PubMed  Google Scholar 

  39. Berntorp E et al (2003) Consensus perspectives on prophylaxis therapy for haemophilia: summary statement. Haemophilia 9(Suppl. 1):1–4

    PubMed  Google Scholar 

  40. Donadel-Claeyssens S (2006) Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 12(2):124–127

    CAS  PubMed  Google Scholar 

  41. Doria AS et al (2005) Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia 11(3):245–253

    CAS  PubMed  Google Scholar 

  42. den Uijl I, Biesma D, Grobbec D, Fischer K (2014) Outcome in moderate haemophilia. Blood Transfus 12(supp 1):330–336

    Google Scholar 

  43. Berntorp E et al (1995) Modern treatment of haemophilia. Bull World Health Organ 73(5):691–701

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Aledort LM (1998) Unsolved problems in haemophilia. Haemophilia 4:341–345

    CAS  PubMed  Google Scholar 

  45. Jones P (1995) Haemophilia: a global challenge. Haemophilia 1:11–13

    CAS  PubMed  Google Scholar 

  46. Manco-Johnson MJ, Abshire TC, Shapiro AD et al (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357(6):535–544

    CAS  PubMed  Google Scholar 

  47. Roosendaal G, Lafeber F (2007) Prophylactic treatment for prevention of joint disease in hemophilia-cost versus benefit. N Engl J Med 357:603–606

    CAS  PubMed  Google Scholar 

  48. Geraghty S, Dunkley T, Harrington C et al (2006) Practice patterns in haemophilia A therapy—global progress towards optimal care. Haemophilia 12(1):75–81

    CAS  PubMed  Google Scholar 

  49. Srivastava A et al (2005) Guidelines for the management of hemophilia. World Federation of Hemophilia. Available via DIALOG. https://www1.wfh.org/publications/files/pdf-1472.pdf. Accessed 21 Aug 2018

  50. (2016) MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). National Hemophilia Foundation. Available via DIALOG. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis. Accessed 3 Feb 2018

  51. Lee CA (1998) Towards achieving global haemophilia care: World Federation of Hemophilia programmes. Haemophilia 4(4):463–473

    CAS  PubMed  Google Scholar 

  52. Petrini P (2007) Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 13(Suppl. 2):16–22

    CAS  PubMed  Google Scholar 

  53. Gouider E, Jouini L, Achour M, Elmahmoudi H, Zahra K, Saied W, Meddeb B (2017) Low dose prophylaxis in Tunisian children with haemophilia. Haemophilia 23(1):77–81

    CAS  PubMed  Google Scholar 

  54. Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J (2011) Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 17(1):70–74

    CAS  PubMed  Google Scholar 

  55. Tang L, Wu R, Sun J, Zhang X, Feng X, Zhang K-H, Luke S, Poon M-C (2013) Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 19:27–34

    CAS  PubMed  Google Scholar 

  56. Poon Man-Chiu, Lee Adrienne (2016) Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thromb J 14(Suppl. 1):32

    PubMed  PubMed Central  Google Scholar 

  57. Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N, Ramesh A, Charles D, Vinod KV, HarichandraKumar KT (2016) A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia—a success story from a resource limited country. Haemophilia 22(3):342–348

    CAS  Google Scholar 

  58. Sidharthan N, Sudevan R, Narayana Pillai V, Mathew S, Raj M, Viswam D, Joseph C, Sudhakar A (2017) Low-dose prophylaxis for children with haemophilia in a resource-limited setting in south India: a clinical audit report. Haemophilia 23:e382–e384

    CAS  PubMed  Google Scholar 

  59. Eshghi P, Sadeghi E, Tara SZ, Habibpanah B, Hantooshzadeh R (2017) Iranian low-dose escalating prophylaxis regimen in children with severe haemophila A and B. Clin Appl Thromb Hemost 24:513–518

    PubMed  PubMed Central  Google Scholar 

  60. Poonnoose P et al (2017) Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage—the MUSFIH study. Haemophilia 3(4):538–546

    Google Scholar 

  61. Apte S et al (2017) Low dose (20 IU/kg/week) single infusion prophylaxis per week using long acting FVIIIc (ELOCTATE, Biogen) in severe Hemophilia A: a cost effective and feasible protocol for resource constraint situation. In: Abstract 2670, ISTH 2017

  62. De D, Datta SS, Basak B, Halder S, Chatterjee P (2018) Very low dose prophylaxis in children with haemophilia A: a rural indian experience. Abstract S890:215843

    Google Scholar 

  63. Abraham A, Apte S, Singh AS, Subramaniam K, Korula A, Joshi A, Khedekar D, Lakshmi KM, George B, Mathews V, Srivastava A (2017) Meaningful reduction of annual bleeding rate with lower dose prophylaxis in minimally treated children with hemophilia in India. Blood 130:1079

    Google Scholar 

  64. Udayakumar S, Pushpalatha K, Vinayaka K, Sushma C, Swathi P (2017) Study to evaluate the effectiveness of coagulation factor concentrate prophylaxis in children with severe hemophilia. Indian J Child Health 4(1):35–38

    Google Scholar 

  65. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G (2010) New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 16(2):256–262

    CAS  PubMed  Google Scholar 

  66. Witmer C, Young G (2013) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4(1):59–72

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Barnes C (2013) Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 60(Suppl. 1):S27–S29

    CAS  PubMed  Google Scholar 

  68. Tezanos Pinto M, Ortiz Z (2004) Haemophilia in the developing world: successes, frustrations and opportunities. Haemophilia 10(4):14–19

    PubMed  Google Scholar 

  69. Ahlberg A (1965) Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 36(Suppl. 77):3–132

    Google Scholar 

  70. O’Mahony B, Black C, O’Mahony B, Black C (2005) Expanding hemophilia care in developing countries. Semin Thromb Hemost 31(5):561–568

    PubMed  Google Scholar 

Download references

Acknowledgements

Dr. D. M. Vasudevan, HOD Medical Research, AIMS, Kochi; Dr. Manu Raj, Professor, Pediatrics and Public Health Research Department, AIMS, Kochi.

Author information

Authors and Affiliations

  1. Department of Haemato Oncology, Amrita Institute of Medical Sciences, Kochi, India

    Neeraj Sidharthan

  2. Department of Health Sciences Research, Amrita Institute of Medical Sciences, Kochi, India

    Remya Sudevan

Authors
  1. Neeraj Sidharthan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Remya Sudevan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeraj Sidharthan.

Ethics declarations

Conflict of interest

The authors stated that they had no interest which might be perceived as posing a conflict or bias.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidharthan, N., Sudevan, R. Low Dose Prophylaxis in Hemophilia Care. Indian J Hematol Blood Transfus 36, 16–25 (2020). https://doi.org/10.1007/s12288-019-01147-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01147-0

Keywords

Search

Navigation